<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">SUN, YING</style></author><author><style face="normal" font="default" size="100%">EICHELBAUM, EHRENTRAUD J.</style></author><author><style face="normal" font="default" size="100%">WANG, HAI</style></author><author><style face="normal" font="default" size="100%">VESELY, DAVID L.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Atrial Natriuretic Peptide and Long Acting Natriuretic Peptide Inhibit MEK 1/2 Activation in Human Prostate Cancer Cells</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">3813-3818</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><issue><style face="normal" font="default" size="100%">6B</style></issue><abstract><style  face="normal" font="default" size="100%">Background: Atrial natriuretic peptide and long acting natriuretic peptide have anticancer effects in human prostate adenocarcinomas. Materials and Methods: Atrial natriuretic peptide, long acting natriuretic peptide and cyclic GMP's effects on MEK 1/2 kinase were examined in human prostate adenocarcinoma cells. Results: Atrial natriuretic peptide and long acting natriuretic peptide decreased the activation of MEK 1/2 over a concentration range of 0.01 μM to 10 μM. Long acting natriuretic peptide and atrial natriuretic peptide (each 10 μM) inhibited the phosphorylation of MEK 1/2 kinase 97% (p&lt;0.00001) and 88% (p&lt;0.00001), respectively. The inhibition of MEK 1/2 was maximal at two hours, and ceased by four hours, secondary to both peptides. The ability of peptides to inhibit MEK 1/2 was inhibited by cyclic GMP antibody and cyclic GMP itself inhibited MEK 1/2 phosphorylation by 93%. Conclusion: Atrial natriuretic peptide and long acting natriuretic peptide both inhibit MEK 1/2 kinase mediated via cyclic GMP as part of their anticancer mechanism(s) of action. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>